John Hussman's NVAX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 42,000 shares of Novavax, Inc. (NVAX) worth $341,880, representing 0.07% of the portfolio. First purchased in 2020-Q1, this short-term holding has been held for 7 quarters.
Based on 13F filings, John Hussman has maintained this position in NVAX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2024, adding 84,000 shares. Largest reduction occurred in Q2 2025, reducing 168,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Novavax (NVAX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novavax (NVAX) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +42,000 | New Buy | 42,000 | $8.14 |
| Q2 2025 | -168,000 | Sold Out | 0 | $0.00 |
| Q1 2025 | +84,000 | Add 100.00% | 168,000 | $6.41 |
| Q3 2024 | +84,000 | New Buy | 84,000 | $12.63 |
| Q2 2020 | -15,000 | Sold Out | 0 | $0.00 |
| Q1 2020 | +15,000 | New Buy | 15,000 | $13.60 |
John Hussman's Novavax Investment FAQs
John Hussman first purchased Novavax, Inc. (NVAX) in Q1 2020, acquiring 15,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Novavax, Inc. (NVAX) for 7 quarters since Q1 2020.
John Hussman's largest addition to Novavax, Inc. (NVAX) was in Q3 2024, adding 84,000 shares worth $1.06 M.
According to the latest 13F filing for Q1 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 42,000 shares of Novavax, Inc. (NVAX), valued at approximately $341,880.
As of the Q1 2026 filing, Novavax, Inc. (NVAX) represents approximately 0.07% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Novavax, Inc. (NVAX) was 168,000 shares, as reported at the end of Q1 2025.